Core Viewpoint - 加科思-B (01167) shares rose over 5% following the announcement of their participation in the 2025 American Association for Cancer Research conference, where they will present preclinical data on their Pan-KRAS inhibitor JAB-23E73 [1] Group 1: Company Developments - 加科思 announced that they will present preclinical data on the oral, absorbable, and potent Pan-KRAS inhibitor JAB-23E73 at the 2025 American Association for Cancer Research conference in Boston from October 22 to October 26, 2025 [1] - The company signed an agreement with Haisheng Capital and an industry partner for a capital increase and equity transfer, where Haisheng Capital will pay a total of RMB 2 billion (1.25 billion upfront and 750 million milestone payment) to acquire 80% of Beijing Jakesi's subsidiary, Jakesi Kang [1] - Following the completion of this transaction, 加科思's ownership in Jakesi Kang will decrease to 10%, allowing the company to focus more on its core oncology business and improve cash flow [1]
港股异动 | 加科思-B(01167)早盘涨超5% 公司发表抑制剂JAB-23E73临床前数据